Total Payments
$4.9M
2024 Payments
$537,093
Companies
49
Transactions
4,249
Medicare Patients
2,900
Medicare Billing
$800,710
Payment Breakdown by Category
Other$2.8M (57.0%)
Consulting$1.1M (22.3%)
Research$389,406 (8.0%)
Travel$387,861 (7.9%)
Education$138,802 (2.8%)
Food & Beverage$96,720 (2.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2.3M | 800 | 46.3% |
| Consulting Fee | $1.1M | 328 | 22.3% |
| Honoraria | $522,156 | 215 | 10.7% |
| Unspecified | $389,406 | 132 | 8.0% |
| Travel and Lodging | $387,861 | 1,170 | 7.9% |
| Education | $138,802 | 10 | 2.8% |
| Food and Beverage | $96,720 | 1,594 | 2.0% |
Payments by Type
General
$4.5M
4,117 transactions
Research
$389,406
132 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ACADIA Pharmaceuticals Inc | $997,289 | 734 | $0 (2024) |
| Teva Pharmaceuticals USA, Inc. | $557,191 | 464 | $0 (2024) |
| US WorldMeds, LLC | $524,730 | 596 | $0 (2020) |
| Neurocrine Biosciences, Inc. | $473,466 | 456 | $0 (2024) |
| MDD US Operations, LLC | $410,287 | 326 | $0 (2024) |
| Kyowa Kirin, Inc. | $341,559 | 225 | $0 (2024) |
| Acorda Therapeutics, Inc | $268,155 | 207 | $0 (2024) |
| Amneal Pharmaceuticals LLC | $254,571 | 176 | $0 (2024) |
| Sunovion Pharmaceuticals Inc. | $242,504 | 76 | $0 (2022) |
| Adamas Pharmaceuticals, Inc. | $208,591 | 209 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $537,093 | 429 | MDD US Operations, LLC ($141,354) |
| 2023 | $489,944 | 406 | MDD US Operations, LLC ($165,923) |
| 2022 | $486,329 | 418 | Neurocrine BioSciences, Inc. ($122,210) |
| 2021 | $582,216 | 411 | ACADIA Pharmaceuticals Inc ($115,879) |
| 2020 | $507,575 | 400 | US WorldMeds, LLC ($98,808) |
| 2019 | $852,877 | 723 | ACADIA Pharmaceuticals Inc ($168,448) |
| 2018 | $772,626 | 722 | ACADIA Pharmaceuticals Inc ($182,130) |
| 2017 | $659,265 | 740 | ACADIA Pharmaceuticals Inc ($227,409) |
All Payment Transactions
4,249 individual payment records from CMS Open Payments — Page 1 of 170
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | ABBVIE INC. | VYALEV (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,400.00 | General |
| Category: NEUROSCIENCE | ||||||
| 12/30/2024 | H. Lundbeck A S | — | Honoraria | Cash or cash equivalent | $266.00 | General |
| 12/26/2024 | Amneal Pharmaceuticals LLC | CREXONT (Drug) | Honoraria | Cash or cash equivalent | $2,275.00 | General |
| Category: NEUROLOGY | ||||||
| 12/24/2024 | ABBVIE INC. | VYALEV (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,600.00 | General |
| Category: NEUROSCIENCE | ||||||
| 12/24/2024 | ABBVIE INC. | VYALEV (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,000.00 | General |
| Category: NEUROSCIENCE | ||||||
| 12/24/2024 | ABBVIE INC. | VYALEV (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,400.00 | General |
| Category: NEUROSCIENCE | ||||||
| 12/17/2024 | ABBVIE INC. | VYALEV (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,000.00 | General |
| Category: NEUROSCIENCE | ||||||
| 12/16/2024 | Amneal Pharmaceuticals LLC | ONGENTYS (Drug) | Honoraria | Cash or cash equivalent | $4,225.00 | General |
| Category: NEUROLOGY | ||||||
| 12/12/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Consulting Fee | Cash or cash equivalent | $6,625.00 | General |
| Category: Neuropsychiatry | ||||||
| 12/12/2024 | MDD US Operations, LLC | — | Consulting Fee | Cash or cash equivalent | $1,380.00 | General |
| 12/11/2024 | Amneal Pharmaceuticals LLC | ONGENTYS (Drug) | Travel and Lodging | In-kind items and services | $415.96 | General |
| Category: NEUROLOGY | ||||||
| 12/10/2024 | ABBVIE INC. | VYALEV (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,000.00 | General |
| Category: NEUROSCIENCE | ||||||
| 12/10/2024 | ABBVIE INC. | VYALEV (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,000.00 | General |
| Category: NEUROSCIENCE | ||||||
| 12/10/2024 | ABBVIE INC. | BOTOX (Biological) | Consulting Fee | Cash or cash equivalent | $800.00 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 12/10/2024 | ABBVIE INC. | VYALEV (Drug) | Food and Beverage | In-kind items and services | $0.09 | General |
| Category: NEUROSCIENCE | ||||||
| 12/07/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Travel and Lodging | In-kind items and services | $303.97 | General |
| Category: Neuropsychiatry | ||||||
| 12/07/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $60.57 | General |
| Category: Neuropsychiatry | ||||||
| 12/07/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $40.37 | General |
| Category: Neuropsychiatry | ||||||
| 12/07/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $36.31 | General |
| Category: Neuropsychiatry | ||||||
| 12/07/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $35.72 | General |
| Category: Neuropsychiatry | ||||||
| 12/07/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $34.72 | General |
| Category: Neuropsychiatry | ||||||
| 12/07/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $30.55 | General |
| Category: Neuropsychiatry | ||||||
| 12/05/2024 | ABBVIE INC. | — | Travel and Lodging | In-kind items and services | $268.71 | General |
| 12/05/2024 | MDD US Operations, LLC | — | Food and Beverage | In-kind items and services | $150.00 | General |
| 12/05/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $59.46 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Apokyn Infusion Development OL AP2-3000 | US WorldMeds, LLC | $106,890 | 60 |
| ACA 16-cAC-0001 | ACADIA Pharmaceuticals Inc | $67,000 | 5 |
| ACP-103-015 | ACADIA Pharmaceuticals Inc | $42,940 | 2 |
| ACP-103-032 | ACADIA Pharmaceuticals Inc | $39,677 | 15 |
| A MULTICENTER, OPEN LABEL, TWO-ARM STUDY TO EVALUATE THE IMPACT OF USING WEARABLE DEVICES IN ADDITION TO STANDARD CLINICAL PRACTICE ON PARKINSON'S SUBJECT SYMPTOMS MANAGEMENT - PHASE 4 | UCB SA | $29,280 | 2 |
| Xadago Pro-Go | US WorldMeds, LLC | $21,902 | 4 |
| ACP-103-045 | ACADIA Pharmaceuticals Inc | $21,730 | 3 |
| ACP-103-033 | ACADIA Pharmaceuticals Inc | $18,929 | 3 |
| Myobloc Sialorrhea OL Protocol SN-SIAL-351 | US WorldMeds, LLC | $16,524 | 7 |
| ACP-103-048 | ACADIA Pharmaceuticals Inc | $13,780 | 9 |
| EFFECT OF LY3154207 ON COGNITION IN MILD TO MODERATE PARKINSONS DISEASE DEMENTIA PDD - THE PRESENCE STUDY | Eli Lilly and Company | $7,610 | 2 |
| Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants With Parkinson's Disease | Biogen, Inc. | $892.96 | 10 |
| Opicapone Treatment Initiation Open-Label Study | Neurocrine Biosciences, Inc. | $560.00 | 1 |
| Multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of GZ SAR402671 in patients with early-stage Parkinson's disease | GENZYME CORPORATION | $536.00 | 1 |
| Multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of GZ SAR402671 in patients with early-stage Parkinson''s disease | GENZYME CORPORATION | $532.43 | 3 |
| Multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of GZ, SAR402671 in patients with early-stage Parkinson?s disea | GENZYME CORPORATION | $332.50 | 2 |
| Phase II study in early stage Parkinson s Disease Patients | Roche TCRC, Inc. | $126.00 | 1 |
| Multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of GZ/SAR402671 in patients with early-stage Parkinson's disease | GENZYME CORPORATION | $96.85 | 1 |
| ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | Eli Lilly and Company | $66.46 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 12 | 584 | 7,899 | $209,931 | $159,389 |
| 2022 | 12 | 780 | 11,915 | $292,978 | $221,441 |
| 2021 | 11 | 854 | 10,498 | $295,301 | $228,396 |
| 2020 | 12 | 682 | 8,543 | $248,929 | $191,485 |
Total Patients
2,900
Total Services
38,855
Medicare Billing
$800,710
Procedure Codes
47
All Medicare Procedures & Services
47 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 172 | 431 | $79,903 | $61,434 | 76.9% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2023 | 133 | 294 | $38,517 | $29,701 | 77.1% |
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2023 | 16 | 4,600 | $30,480 | $22,306 | 73.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 130 | 205 | $27,109 | $20,085 | 74.1% |
| J0588 | Injection, incobotulinumtoxin a, 1 unit | Office | 2023 | 14 | 2,200 | $11,902 | $8,818 | 74.1% |
| 64616 | Injection of chemical for paralysis of nerve muscles on side of neck excluding voice box | Office | 2023 | 12 | 29 | $6,438 | $5,047 | 78.4% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 37 | 47 | $4,396 | $3,300 | 75.1% |
| 64611 | Injection of chemical for paralysis of salivary glands on both sides of mouth | Office | 2023 | 18 | 27 | $3,840 | $3,011 | 78.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 11 | 11 | $2,524 | $1,907 | 75.6% |
| 11104 | Punch biopsy, first skin growth | Office | 2023 | 15 | 15 | $1,956 | $1,534 | 78.4% |
| 11105 | Punch biopsy, each additional skin growth | Office | 2023 | 15 | 27 | $1,649 | $1,293 | 78.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 11 | 13 | $1,216 | $953.29 | 78.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 171 | 381 | $72,162 | $56,285 | 78.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 189 | 369 | $49,225 | $37,533 | 76.2% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2022 | 160 | 347 | $46,284 | $36,371 | 78.6% |
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2022 | 14 | 6,400 | $44,800 | $31,177 | 69.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 80 | 80 | $18,709 | $14,305 | 76.5% |
| J0587 | Injection, rimabotulinumtoxinb, 100 units | Office | 2022 | 16 | 1,425 | $18,525 | $13,649 | 73.7% |
| J0588 | Injection, incobotulinumtoxin a, 1 unit | Office | 2022 | 13 | 2,700 | $16,200 | $10,763 | 66.4% |
| 64616 | Injection of chemical for paralysis of nerve muscles on side of neck excluding voice box | Office | 2022 | 14 | 38 | $8,772 | $6,940 | 79.1% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2022 | 68 | 86 | $8,118 | $6,418 | 79.1% |
| 64611 | Injection of chemical for paralysis of salivary glands on both sides of mouth | Office | 2022 | 19 | 48 | $6,911 | $5,411 | 78.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 20 | 24 | $2,282 | $1,801 | 78.9% |
| 99441 | Telephone medical discussion with physician, 5-10 minutes | Office | 2022 | 16 | 17 | $990.59 | $786.95 | 79.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 221 | 592 | $80,192 | $63,075 | 78.7% |
About Dr. Stuart Isaacson, MD
Dr. Stuart Isaacson, MD is a Neurology healthcare provider based in Boca Raton, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/09/2006. The National Provider Identifier (NPI) number assigned to this provider is 1023059169.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Stuart Isaacson, MD has received a total of $4.9M in payments from pharmaceutical and medical device companies, with $537,093 received in 2024. These payments were reported across 4,249 transactions from 49 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($2.3M).
As a Medicare-enrolled provider, Isaacson has provided services to 2,900 Medicare beneficiaries, totaling 38,855 services with total Medicare billing of $800,710. Data is available for 4 years (2020–2023), covering 47 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Boca Raton, FL
- Active Since 06/09/2006
- Last Updated 11/04/2011
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1023059169
Products in Payments
- NUPLAZID (Drug) $965,872
- AUSTEDO (Drug) $433,081
- APOKYN (Drug) $362,085
- INGREZZA (Drug) $345,789
- GOCOVRI (Drug) $340,523
- INBRIJA (Drug) $242,584
- NOURIANZ (Drug) $225,751
- RYTARY (Drug) $204,057
- NORTHERA (Drug) $148,785
- Xadago (Drug) $114,489
- Nourianz (Drug) $113,819
- MYOBLOC (Biological) $102,183
- ONGENTYS (Drug) $93,698
- Austedo XR (Drug) $91,704
- Gocovri (Drug) $82,027
- BOTOX (Biological) $65,316
- Neupro (Drug) $52,286
- CREXONT (Drug) $36,875
- VYALEV (Drug) $34,232
- Duopa (Drug) $31,538
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Boca Raton
Brian Steingo, Md, MD
Neurology — Payments: $1.4M
Neurology $1.4M
Dr. Brian Costell, M.d, M.D
Neurology — Payments: $638,608
Neurology $638,608
Dr. Patricio Espinosa, Md,Mph, MD,MPH
Neurology — Payments: $215,050
Neurology $215,050
Dr. Richard Isaacson, M.d, M.D
Neurology — Payments: $140,056
Neurology $140,056
Gediminas Gliebus, M.d, M.D
Neurology — Payments: $120,507
Neurology $120,507
Dr. Richard Dewey, Md, MD
Neurology — Payments: $45,477
Neurology $45,477